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1. ABSTRACT 
1.1 Background 
Hepatitis C virus (HCV) infection affects 170 million people worldwide. 
A combination of pegylated interferon and ribavirin is the current standard 
therapy for HCV infection but provides relatively low efficacy, especially in 
the patients infected with HCV genotype 1, the most prevalent genotype 
worldwide. Sustained virological response rate achieved with the standard 
therapy is around 50% for the patients infected with HCV genotype 1. 
Therefore, the development of novel therapeutic agents is required for 
further improvement in the treatment of chronic HCV infection. 
1.2 Objective  
In this study, I analyzed the inhibitory effects of procyanidin B1 (PB1) 
on the HCV replication and which step of HCV replication is inhibited by 
PB1. 
1.3 Methods 
HCV pseudotype virus assay was used to analyze the viral entry step. 
HCV subgenomic replicon assay was used to analyze the HCV RNA 
replication in this study.  
1.4 Results 
PB1, a dimer of (-)-epicatechin and (+)-catechin, purified from 
Cinnamomi Cortex inhibited HCV pseudotype virus infection in Huh-7 cells, 
with 50% effective concentrations of 15 ± 3.9 µM. I revealed that PB1 
interferes little with the viral entry but inhibits HCV RNA replication in a 
dose-dependent manner. The single component, either (-)-epicatechin or (+)-
catechin, has little effects on HCV RNA replication
1.5 Conclusion 
. 
These results indicate that PB1 might act as an HCV RNA 
replication inhibitor. This study may pave the way to develop more effective 
inhibitors for HCV infection from natural plants.  
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2. INTRODUCTION 
 
2.1 Profile of hepatitis C virus 
 
Hepatitis C virus (HCV) is the major causative agent of post-
transfusional non-A, non-B viral hepatitis [1-3]. HCV is a member of the 
Hepacivirus genus of the Flaviviridae family. The most closely related 
human viruses are hepatitis G virus, yellow fever virus, and dengue virus [4]. 
HCV virions are 40–70 nm in diameter [5]. HCV is a single-stranded, 
positive-sense RNA virus with a genome of approximately 9600 nucleotides. 
The RNA genome is flanked by highly conserved non-coding regions 
(NCRs) important for both viral translation and RNA replication. The 5’-
NCR is comprised of four highly structured domains forming the internal 
ribosome entry site (IRES), which is a virus-specific structure to initiate 
HCV viral translation. The 3’-NCR consists of a short variable sequence, a 
poly (U)-poly (UC) tract, and a highly conserved X region and is critical for 
HCV RNA replication [6].  
 
HCV does not integrate into the host genome and HCV replication 
proceeds entirely in the cytoplasm (as depicted in Fig. 1). So far, CD81 [7], 
claudin-1 [8], glycosaminoglycans [9], scavenger receptor class B type I 
(SR-BI) [10], have been proposed as HCV receptors. However, certain cell 
types were found to be non-permissive despite expression of all of these 
potent receptors indicating that additional hepatocyte-specific factors must 
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be required for HCV entry [8]. HCV enters by a clathrin-dependent 
endocytosis way. After binding to the receptors, fusion with cellular 
membranes, and uncoating of the viral nucleocapsid, the single-stranded 
positive-sense RNA genome is released into the cytoplasm to be used as a 
messenger RNA for the HCV polyprotein translation.  
 
The translation is a cap-independent IRES-mediated process [11, 12]. 
The viral genome encodes a polyprotein precursor of approximately 3010 
amino acids, which is processed by cellular and viral proteases to produce 
structural and nonstructural proteins. The structural proteins, which form the 
viral particle, include the core protein and the envelope glycoproteins E1 and 
E2. The core protein forms the viral nucleocapsid. The envelope proteins E1 
and E2 form a non-covalent complex, which are important for viral entry. 
The nonstructural (NS) proteins, which are mainly viral enzymes important 
for HCV RNA replication, include p7, NS2, NS3, NS4A, NS4B, NS5A and 
NS5B. p7 is a small hydrophobic protein that forms an ion channel through 
the viral lipid membrane [13, 14]. NS2 is a metalloproteinase that cleaves 
itself from the NS2 ⁄ NS3 protein, leading to the release of NS3 protein [15, 
16]. NS3 and NS4A form the serine protease. Besides its essential role in 
protein processing, NS3 has the helicase activity of unwinding of viral RNA 
in the HCV RNA replication complex [17]. NS4B induces the formation of 
membranous web, the specific membrane alteration which is used as a 
scaffold for the HCV replication complex [18]. The function of NS5A 
remains unknown but is important for HCV RNA replication [19, 20]. NS5B 
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is an RNA-dependent RNA-polymerase which catalyses the synthesis of a 
complementary negative-strand RNA using the positive-strand RNA genome 
in the membranous web. Subsequently, using the newly produced negative-
strand RNA as a template, numerous positive-strand RNAs are synthesized 
by NS5B and then used as templates for further replication and protein 
translation.  
 
Little is known about the late steps of HCV life cycle. It is believed that 
the oligomerization of the capsid protein and encapsidation of genomic RNA 
form the nucleocapsid assembly. Then HCV virions get the outer envelope 
composed of a lipid cell membrane and HCV envelope glycoproteins while 
they are released through an intracellular membrane [21]. However, the 
detailed mechanisms of the assembly and particle release steps remain 
unknown because of lacking the efficient assay systems. The natural targets 
of HCV are hepatocytes and, possibly, B lymphocytes [22, 23]. HCV strains 
are classified into six major genotypes and multiple subtypes on the basis of 
molecular relatedness. Differences of the nucleotide sequences in the six 
major HCV genotypes are 30-35% [24].  
 
2.2 The treatment of HCV infected patients  
 
Most acute HCV infections are asymptomatic. Acute infection leads to 
chronic infection in almost 80% of patients [25]. Chronic HCV infection is 
characterized by inflammatory lesions in the liver, often accompanied by 
 6 
steatosis and progressive fibrosis of variable degrees. Chronic infection 
usually progresses to cirrhosis and finally hepatocellular carcinoma (HCC) 
[26, 27]. HCV infection, affecting about 170 million people worldwide, is 
the main cause of adult liver transplants in developed nations [3]. Currently, 
no protective vaccine against HCV is available, and the standard therapy is a 
combination of interferon (IFN) and ribavirin [28, 29].  The best indicator of 
effective treatment is to achieve sustained virological response (SVR). SVR 
is defined as the loss of detectable plasma HCV RNA during the treatment 
and its continued absence for at least 6 months after the cessation of therapy. 
The SVR rate is dependent on the HCV genotypes. For HCV genotype 1, the 
SVR rates are between 44% and 56% within 48 weeks of the standard 
therapy, whereas for genotypes 2 and 3 they are between 61% and 76% 
within only 24 weeks [30, 31]  indicating that the current standard therapy 
seems to be insufficient for HCV infected patients, especially genotype 1. 
Moreover, the regimen has poor tolerability for a long term treatment, which 
induces significant side effects often leading to dose reductions or 
discontinuation of treatment in approximately 10-14% of patients [28, 30]. 
Therefore, more-effective and better-tolerated therapies for HCV are 
urgently needed. Currently, a step forward treatment, named specifically 
targeted antiviral therapy for hepatitis C virus (STAT-C), is promising [32]. 
The main targets of this treatment are HCV NS3/4A serine protease and 
NS5B RNA polymerase. These direct antivirals are currently in phase I-III 
clinical trials. The addition of the STAT-C drugs to the standard therapy 
significantly increases the SVR rates and shortens duration of therapy in 
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patients infected with HCV genotype 1[33, 34]. This indicates that STAT-C 
might become a promising treatment of HCV infection in future.  
 
2.3 Research progress to development of novel anti-HCV agents 
 
Recent progress in the establishment of in vitro systems for HCV 
replication assays has accelerated the study of HCV life cycle. For the viral 
entry study, the pseudotype virus assay is an ideal system. HCV pseudotype 
virus, consisting of HCV envelope and vesicular stomatitis virus (VSV) or 
retrovirus genomes, can make only a single round of replication without 
producing infectious viruses because it lacks the viral envelope genes. 
Therefore, HCV pseudotype virus assay is an excellent system for studying 
the entry step and developing new antivirals counteracting viral entry [35, 
36]. For the viral RNA replication study, the HCV replicon system is an 
important breakthrough due to lacking a robust cell culture system for a long 
time. Replicon is a subgenomic construct expressing the viral nonstructural 
genes and capable of autonomous viral replication. HCV replicon usually 
carries luciferase reporter gene. Luciferase assay and quantitative real-time 
PCR assay have shown that luciferase activity is highly correlated with HCV 
RNA level [37]. This makes HCV replicon RNA to be measured easily and 
quickly. HCV replicon is a useful system for studying HCV RNA replication 
and testing antiviral drugs against HCV major enzymes, such as NS3/4A 
protease and NS5B polymerase. HCV cell culture system for a productive 
infection was first established based on an HCV genome of JFH1 strain 
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(genotype 2a) in 2005 [5, 38]. However, robust and reliable in vitro cell 
culture systems have not yet been established for the authentic viruses of the 
genotype 1, which is the most prevalent HCV genotype in the world. These 
new advances have led the way toward the development of more effective, 
specific anti-HCV agents.  
 
 
 
3. OBJECTIVES OF THE STUDY 
 
In our previous study, two herbal extracts screened from seven 
medicinal herbs showed moderate inhibitory activities against severe acute 
respiratory syndrome coronavirus (SARS-CoV) replication in vitro [39]. 
Procyanidin purified from Cinnamomi Cortex seems to be the main active 
component for SARS-CoV inhibitory effect. Procyanidin, also known as 
oligomeric proanthocyanidin and condensed tannin, is a class of flavanols, 
which take the form of oligomers or polymers of flavonoids. Procyanidin B1 
(PB1), a B type procyanidin, is a dimer of (-)-epicatechin and (+)-catechin 
by C4-C8 linkage. In this study, I analyzed the inhibitory effects of PB1 on 
HCV replication using two main HCV assays, HCV pseudotype virus and 
subgenomic replicon assay, and had a further study of the mechanisms of 
action of PB1 on HCV replication.  
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4. MATERIALS AND METHODS 
 
4.1 Cells and reagents 
 
Human hepatocarcinoma cell lines (Huh-7) and 293T cells were 
maintained in Dulbecco’s Modified Eagle Medium supplemented with 10% 
heat-inactivated fetal bovine serum (GIBCO BRL, Grand Island, NY), 100 
U/ml penicillin G, 100 µg/ml streptomycin and L-glutamine (GIBCO BRL) 
according to ATCC recommendations. Chlorpromazine, methyl-β-
cyclodextrin (MβCD), ribavirin, (-)-epicatechin (Fig. 2B) and (+)-catechin 
(Fig. 2C) were purchased from Sigma (Sigma, St. Louis, MO), dissolved in 
water and filtrated. Phycoerythrin (PE)-conjugated CD81monoclonal 
antibody (mAb) (clone JS64) was purchased from Beckman Coulter 
(Beckman Coulter, Fullerton, CA). PE-conjugated CD71 mAb (clone M-
A712), PE-conjugated mouse IgG2a, κ mAb (clone G155-178) and 7-AAD 
were purchased from BD Pharmigen (BD Pharmigen, San Diego, CA). 
Plasmids (pCMV-VSV-G, pCAG-HIVgp and pCS-II-luciferase) were 
obtained from RIKEN, Japan.  
 
4.2 Purification of PB1 
 
PB1 was purified from Cinnamomi Cortex as described previously [40] 
and its structure is shown in Fig. 2A. Briefly, the dried medicinal herb 
Cinnamomi Cortex was extracted three times under reflux with 60% acetone 
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at 50 °C for 2 h. The extract was concentrated under reduced pressure until 
the organic solvent was removed, and precipitates formed in the resulting 
aqueous solution were dissolved by the addition of methanol. The solution 
was applied to Sephadex LH-20 column chromatography with water and 
finally with 50% aqueous acetone. The fractions containing procyanidins, 
which were positive to FeCl3 and vanillin/HCl reagents, were collected and 
concentrated until the organic solvent was completely removed. The 
aqueous layer was lyophilized and subjected to gel permeation 
chromatography on Sephadex LH-20 with acetone/7 M urea to yield crude 
procyanidin B1, followed by further recrystallization to yield purified PB1. 
The structure was determined by 13
 
C nuclear magnetic resonance. The purity 
of PB1 is around 90% in high-performance liquid chromatography assay. 
4.3 Pseudotype virus infection assay 
 
Dr. Matsuura and colleagues in Osaka University previously 
established VSV-based pseudotype viruses bearing HCV envelope proteins 
E1 and E2 (HCVpv) or VSV glycoprotein G (VSVpv), which exhibited high 
infectivity in Huh-7 cells [41]. Briefly, 293T cells were transfected with an 
expression plasmid encoding the HCV E1 and E2 genes of Con1 strains 
(genotype 1b). Numerous HCV envelope proteins were produced in the 
cytoplasm and then expressed on the surface of 293T cell membrane. The 
293T cells were  subsequently infected with a VSV-G-complemented 
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pseudotype virus (VSV△G /GFP-G). The VSV genome (envelope gene 
replaced by GFP reporter gene) replicated in 293T cells and the newly 
produced RNAs were packaged into the nucleocapsid with the help of viral 
packaging signal. The HCVpv was then released from 293T cells and can 
infect Huh-7 cells but produce no infectious progeny virus because of 
lacking viral envelope genes. VSV△G /GFP-G was produced in 293T cells 
transfected with the plasmids of pVSV△G /GFP and pCAG-VSV-G and 
used as a control in the pseudotype virus assay. The green fluorescent 
protein (GFP) gene in each pseudotype virus was replaced by the firefly 
luciferase gene. The viral genomes in HCVpv and VSVpv are same. The 
envelopes in HCVpv and VSVpv are different, with HCV E1 E2 and VSV 
glycoprotein G, respectively (as depicted in Fig. 3A). I obtained this 
pseudotype virus system from Dr. Matsuura and applied this system to 
conduct the current study. Prior to HCVpv or VSVpv infection, Huh-7 cells 
were incubated with PB1 at 37°C for 1 h. After 48 h of the pseudotype virus 
infection, cells were harvested, lysed and subjected to the Luciferase 
Reporter Assay system (Promega, Madison, WI) with the Mithras LB940 
reader (Berthold Technologies, Bad Wildbad, Germany). The 50% effective 
concentration (EC50
 
) was defined as the concentration that reduced viral 
replication by 50%. Experiments were performed in triplicate. The 
percentages of relative luciferase units (RLU) from means of three 
independent experiments are shown. 
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4.4 Entry assay based on intracellular p24 gag  
 
For the viral entry assay, I constructed the HIV-1 based pseudotype 
virus bearing VSV envelope protein G (VSV-G/HIVpv) in 293T cells. First, 
293T cells were transfected with 0.5 µg of pCMV-VSV-G, 1 µg of pCAG-
HIVgp and 1.7µg of pCS-II-luciferase using the lipofectamine 2000 
transfection reagent (Invitrogen, Carlsbad, CA). After 3 days of the 
transfection, the supernatants were collected, filtrated with a 0.45 µm 
Millipore filter and stocked in -80°C. The virus titer of VSV-G/HIVpv was 
determined by 
Chlorpromazine, a cationic amphiphilic compound, inhibits clathrin-
dependent endocytosis by preventing the assembly of clathrin-coated pits at 
the cellular membranes [42]. MβCD disrupts cholesterol-rich microdomains 
and inhibits both caveola and lipid-raft-dependent endocytosis [43]. 
Chlorpromazine and MβCD were used as positive and negative controls of 
clathrin-dependent endocytosis in this entry assay. To determine the effects 
of compounds on viral endocytosis, Huh-7 cells were pretreated with various 
concentrations of compounds (PB1, chlorpromazine or MβCD) for 1 h at 
37°C in 48-well plates and then inoculated at 37°C for 4 h with VSV-
G/HIVpv (5 ng of p24 per well). After 4 h of the inoculation, the cells were 
washed twice with phosphate buffered saline (PBS) and treated with 0.25% 
trypsin-EDTA (GIBCO BRL) at 37°C for 5 minutes to degrade the 
unincorporated virus particles. To determine the effects of PB1 on virus 
a Retro-Tek HIV-1 p24 ELISA Kit (ZeptoMetrix, NY).  
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binding, Huh-7 cells were incubated with PB1 and VSV-G/HIVpv (5 ng of 
p24 per well) on ice for 4 h. Intracellular p24 of HIV-1 gag protein was 
measured using a Retro-Tek HIV-1 p24 ELISA Kit (ZeptoMetrix, 
NY).  
4.5 Time of addition assay 
Experiments were performed independently at least three times.  
 
 
To evaluate which steps of virus replication were inhibited by the 
compound, a time of addition experiment was carried out in Huh-7 cells. 
Huh-7 cells were seeded at a density of 1×104
4.6 Cytotoxicity assay 
 per well in 96-well plates on 
the day before the virus infection. PB1 (100 µM) was added in triplicate at 0, 
1, 4, 8, 12 and 24 h after VSVpv or HCVpv infection in Huh-7 cells. After 
48 h, the cells were washed with PBS and subjected to the luciferase assay 
with the Luciferase Reporter Assay system (Promega) as described 
previously [44, 45]. Experiments were performed independently at least 
three times. 
 
 
The cytotoxicity of the compounds was examined in Huh-7 cells using 
the Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc, Kumamoto, 
Japan). Firstly, 100 µl of Huh-7 cell suspension (5000 cells per well) was 
dispensed in a 96-well tissue culture plate and pre-incubated for 24 h in a 
humidified incubator (37°C, 5% CO2). Secondly, 10 µl of various 
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concentrations of compounds was added into the culture medium in the 
plates and incubated for 72 h. Thirdly, 10 µl of CCK-8 solution was added to 
each well of the plates. Finally, after 2 h of the incubation at 37°C, the 
absorbance was measured at 450 nm using a microplate reader. The 50% 
cytotoxicity concentration (CC50
4.7 Flow cytometric analysis 
) was defined as the concentration that 
reduced cell viability by 50%. 
 
 
Huh-7 cells were pretreated with or without PB1 (100 µM) at 37°C for 
1 h. After washing with FACS buffer (PBS supplemented with 2% fetal 
bovine serum and 0.1% sodium azide), the adherent cells were detached with 
1 mM EDTA (GIBCO BRL) for 30 min on ice. Cells were centrifuged at 
4°C and the supernatants were discarded.  The cell pellet was suspended in 
50µl FACS buffer and incubated with 10 µl of PE-conjugated CD81 or 
CD71 monoclonal antibodies for 30 min at 4°C. Cells were subsequently 
washed twice with FACS buffer, and subjected to flow cytometric analysis 
(Cytomics FC500, Beckman Coulter). PE-conjugated mouse IgG2a, κ 
monoclonal antibody was used as the isotype control. 7-AAD was used as a 
viability probe for dead cell exclusion. 
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4.8 HCV replicon assay 
 
An understanding of the biology of HCV replication has been 
facilitated by the development of subgenomic HCV replicons, which express 
HCV nonstructural proteins and replicate their RNA autonomously when 
transfected into Huh7 cells. Dr. Shimotohno and colleagues in Kyoto 
University constructed the HCV replicon from cultured cells infected with 
HCV [46, 47]. I obtained the HCV replicon plasmid pLMH14 from Dr. 
Shimotohno. The plasmid pLMH14 contains the genes of the 5’-NCR, the 
first 36 nucleotides of the core region fused directly with the firefly 
luciferase reporter gene, the IRES element from encephalomyocarditis virus 
(EMCV) that directs translation of the HCV nonstructural proteins from NS3 
to NS5B, and the 3’-NCR of HCV genome as depicted in Fig. 3B. The 
replicon-encoded firefly luciferase expression is highly correlated with HCV 
RNA levels and used as a read out of HCV RNA levels [37]. I performed the 
HCV replicon assay as described previously [48]. Briefly, pLMH14 was 
linearized at the restriction endonuclease site Xba I.  The purified linearized 
DNA was used as a template and transcribed by T7 RNA polymerase in 
vitro to synthesize HCV replicon RNA using SP6/T7 transcription kit 
(Roche, Mannheim, Germany). Replicon RNA was purified by repeated 
ethanol precipitation. The concentration of replicon RNA was determined by 
NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, 
DE). Huh-7 cells were transfected by 0.5 µg of HCV replicon RNA per well 
in 24-well plates with a lipofectamine 2000 transfection reagent (Invitrogen, 
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Carlsbad, CA). After 5 h, the medium was replaced and serially diluted PB1, 
ribavirin, (-)-epicatechin or (+)-catechin were added onto Huh-7 cells. The 
luciferase activity was determined at 3 h and 72 h after the transfection. The 
luciferase activities at 3 h were used for the normalization of the transfection 
efficiency. The EC50
5. RESULTS  
 was defined as the concentration that reduced viral 
RNA replication by 50%. Experiments were performed independently at 
least three times. 
 
 
5.1 PB1 suppressed VSVpv and HCVpv infection   
 
A pseudotype virus can make only a single round of infection without 
producing infectious progeny viruses in infected cells making it an excellent 
system for studying the viral entry steps. Here, the effects of PB1 on the 
pseudotype virus infection were firstly studied. Two pseudotype viruses 
were used: VSVpv comprised of VSV envelope protein G and env deleted 
VSV genome (∆G-VSV), and HCVpv comprised of HCV envelope protein 
E1 E2 and ∆G-VSV genome. In this assay, PB1 inhibited both VSVpv and 
HCVpv infection at the non-cytotoxicity concentrations in a dose-dependent 
manner (Fig. 4). The EC50
 
 for VSVpv and HCVpv was 29 ± 7.3 µM and 15 
± 3.9 µM, respectively. These results indicate that PB1 suppresses VSV and 
HCV pseudotype virus infection in Huh-7 cells.  
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5.2 PB1 might inhibit viral replication at post-entry steps 
 
Pseudotype virus infection mainly consists of the viral entry step and 
intracellular RNA genome replication step. To determine which step of virus 
infection was suppressed by PB1, the time of addition experiment was 
performed. This assay provides time-dependent activity that enables 
estimation of the inhibitory steps of compounds. As shown in Fig. 5, the 
luciferase activity was suppressed to less than 50% even when PB1 was 
added after 4, 8 or 12 h of virus infection either for VSVpv or HCVpv. A 
previous study showed that nearly 90% of VSV and HCV were internalized 
into Huh-7 cells within 1.5 h and 3 h, respectively [49]. This indicates that 
the luciferase activity was suppressed to less than 50% when PB1 was added 
after the pseudotype virus internalization was completely finished. These 
results suggest that PB1 may inhibit viral replication at post-entry steps 
rather than the entry step.  
 
5.3 PB1 had little effects on the viral entry 
 
Entry of both VSV and HCV depends on a clathrin-dependent 
endocytosis [42, 50]. To examine the effects on viral entry, I therefore used 
the pseudotype virus of VSV-G/HIVpv since the HIV-1 based pseudotype 
virus bearing HCV E1E2 is not available. VSV-G/HIVpv contains HIV-1 
gag protein p24. After 4 h of infection during the reverse transcription step 
of the HIV-1 genome, I measured the amount of intracellular p24, which is 
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highly correlated with the amount of entered virus particles [51]. Consistent 
with previous reports [43], chlorpromazine decreased the intracellular p24 
level in a dose-dependent manner (Fig. 6A), while MβCD did not (Fig. 6B). 
PB1 little affected the intracellular p24 levels (Fig. 6C). Moreover, the 
binding of VSV-G/HIVpv at 4°C was maintained even in the presence of 
PB1 (Fig. 6D). These results indicate that PB1 had little effects on the viral 
binding and endocytosis for VSV.  
 
To determine whether PB1 interacts with CD81, one of the main HCV 
receptors [7], flow cytometric assay was performed. CD71 (transferrin 
receptor, TfR) was used as a negative control since it was shown that PB1 
did not affect CD71 [39]. The proportion of CD81 positive-staining cells and 
mean fluorescence intensity were little changed by PB1 treatment (Table 1). 
This suggests that PB1 might not interact with HCV main receptor CD81, at 
least for the JS64 epitope on CD81. 
 
5.4 PB1 inhibited HCV RNA replication 
 
Since the time of addition assay and viral entry assay suggested that 
PB1 suppressed viral post-entry steps, I next examined the effects of PB1 on 
HCV RNA replication. Although ribavirin has been used as a combination 
therapy with IFN to inhibit HCV RNA replication in vivo, it has little effect 
on HCV RNA replication in the replicon system in vitro [52, 53]. 
 19 
Consistent with the previous report, the inhibitory effect of ribavirin seems 
to be induced by its cytotoxicity in this study (Fig. 7A). However, PB1 
suppressed the replication of HCV replicon in a dose-dependent manner at 
the non-cytotoxicity concentrations (Fig. 7B). The EC50 and CC50 were 72 ± 
7.4 µM and 465 ± 79 µM, respectively, with the result that the selective 
index (CC50/EC50
 
) was calculated to be 6.5. Since PB1 is composed of (-)-
epicatechin and (+)-catechin by C4-C8 linkage (Fig. 2A), I examined each 
component for their anti-HCV activities. The single component, either (-)-
epicatechin or (+)-catechin, had little inhibitory effects on HCV replicon 
(Fig. 7C, D) indicating that the dimer structure of PB1 is required for anti-
HCV activity. These results suggested that PB1 might inhibit HCV RNA 
replication.  
 
 
 
 
 
 
 
 
 
 
 
 20 
6. DISCUSSION 
 
Hepatocellular carcinoma is one of the most common causes of cancer 
death. In Japan, HCC is the fourth leading cause of death in males and the 
fifth in females [54]. The prevalence of HCC in Japan has increased over the 
past 50 years and more than 30,000 patients die because of HCC every year, 
accounting for rates of death of 36.3 and 17.5 per 100,000 males and 
females, respectively [55]. The main causes of HCC in Japan are HCV and 
hepatitis B virus (HBV) infection and nearly 70% of HCC cases are caused 
by HCV infection [55]. Japan has one of the highest endemic rates of HCV 
infection in the world. The number of patients with HCV infection is 
estimated to be about 2,000,000 in Japan in which 70% of patients are 
infected with HCV genotype 1b, 20% with genotype 2a.  
 
Procyanidins, which are oligomers or polymers of monomeric 
flavonoids, exert strong antioxidant and radical scavenging activities 
compared to vitamin C and E [56]. A procyanidin derivative, PB1, has 
inhibitory effects on the replication of herpes simplex virus (HSV), HIV-1 
and SARS-CoV [39, 57, 58]. However, to date, the anti-HCV activity 
of PB1 has not been documented. In this study I demonstrated that PB1 
inhibits HCV infection for the first time and investigated its antiviral 
mechanism step by step. First, I performed the pseudotype virus assay, 
which showed that PB1 suppresses VSV and HCV pseudotype virus 
infection in Huh-7 cells. The time of addition assay showed that PB1 has 
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strong inhibitory effects on virus infection even PB1 was added after the 
virus completely entered Huh-7 cells indicating that PB1 might inhibit the 
post-entry steps but not the entry step. Next, the viral binding and 
endocytosis assay using the pseudotype virus demonstrated that PB1 has 
little effects on virus binding and endocytosis for VSV. In the flow 
cytometric assay, one CD81 mAb (clone JS64) which recognizes only one 
epitope (JS64) on CD81 was used. In this experiment, PB1 had little effect 
on JS64 epitope on CD81. There are many other mAbs that recognize 
different epitopes of CD81. However, since the entry assay using the 
pseudotype virus and the time of addition assay suggest that PB1 has little 
effects on viral entry, I did not examine the effects of PB1 on different 
epitopes on CD81 using other mAbs. Viral entry assay using the pseudotype 
virus can analyze the entire viral entry steps, while the flow cytometric assay 
analyzes only the interaction between the compound and the viral receptors, 
which is one of entry steps. Since my results indicate that viral entry step is 
not inhibited by PB1, PB1 is less likely to interact with virus receptors. The 
HCV life cycle mainly consists of entry, translation, RNA replication, 
assembly and release steps. Therefore, the effects of PB1 on HCV RNA 
replication were further examined using HCV replicon assay. The HCV 
replicon assay showed that PB1 might inhibit HCV RNA replication. Since 
HCV replicon assay has been well established to mimic the real viral RNA 
replication, and the luciferase activity has been proved by many researchers 
to be highly correlated with HCV RNA level [37], PB1 is likely to be an 
HCV RNA replication inhibitor. Moreover, the dimer structure of PB1 is 
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important for its antiviral activity since the single component, either (-)-
epicatechin or (+)-catechin, has little inhibitory effects on HCV 
replicon. Procyanidins have many isomeric forms depending on the extent of 
polymerization (dimers to petadecamers) and the nature of their constituent 
units [59]. Some biological activities are related to the degree of 
polymerization. In my study, 
I examined the effects of PB1 on viral entry and RNA replication steps, 
but did not examine the effects on viral translation, virus trafficking, 
assembly and release steps. The reason is that currently there are few such 
research tools and the mechanisms of these steps are still not well 
understood. HCV virus was found in 1989, but only in recent years the HCV 
in vitro research systems such as pseudotype virus, HCV replicon, and JFH-
1 cell culture virus have been established and well used by many 
laboratories. Both pseudotype virus assay and HCV replicon assay do not 
contain the assembly and release steps. However, in my study, PB1 shows 
the polymerization of catechins also plays an 
important role in the antiviral activity. The highly polymerized procyanidins 
(trimer, tetramer, etc.) should be examined because they might have higher 
antiviral activities. Previous reports demonstrated that the structural factors 
enhancing the antiviral activities of procyadinins were the galloylation, 
polymerization and mode of linkage, such as a double linkage or C4-C6 
linkage [58]. Therefore, these kinds of chemical modifications of PB1 
structure might also enhance the anti-HCV activity and should be 
investigated in future.  
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inhibitory effects in both assays indicating that the main target may be HCV 
RNA replication step, although the possibility of inhibition of assembly and 
release steps cannot be excluded. Since PB1 is demonstrated to be an RNA 
replication inhibitor by the viral assay, I should perform the in vitro 
enzymatic reaction using HCV RNA polymerase. Unfortunately, HCV RNA 
polymerase is not readily available. I could not do this chemical experiment.  
 
The currently recommended therapy for chronic hepatitis C is a 
combination of pegylated IFN and ribavirin for 24 or 48 weeks [29]. IFN has 
potent antiviral activities but indirectly inhibits viral replication. IFN induces 
IFN-stimulated genes (ISGs), which establish a non-virus-specific antiviral 
state in the cells [60]. The broad antiviral activity of ribavirin led to trials of 
ribavirin monotherapy for HCV in the early 1990s. The enhanced 
therapeutic response by the addition of ribavirin to IFN was surprising 
because ribavirin monotherapy improved serum aminotransferase levels in at 
least half of patients, but viral levels did not change and patients did not 
eliminate HCV RNA even with prolonged treatment with rivabirin [61, 62].  
Ribavirin is currently used only as a combination with IFN. How ribavirin 
enhances the response rate to IFN remains unknown. Several possible 
antiviral mechanisms of ribavirin have been proposed such as: 1) inhibition 
of inosine monophosphate dehydrogenase (IMPDH), leading to depletion of 
guanosine triphosphate (GTP) necessary for viral RNA synthesis [63, 64], 2) 
induction of lethal mutagenesis in the viral RNA genome [65, 66], and 3) 
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alteration of the TH1/ TH2 balance favoring a TH1 CD4＋ response and thus 
leading to viral clearance [29, 66]. However, ribavirin does not significantly 
inhibit the replication of HCV replicon RNA at non-cytotoxicity 
concentrations in vitro [52, 53] and has only weak activity against HCV 
RNA polymerase [67]. 
On the other hand, t
 This is consistent with the clinical observation that 
ribavirin monotherapy is not effective in reducing HCV viremia [3].   
 
he mechanism of action of PB1 appears to be 
distinct from those of IFN and ribavirin. In my study, PB1 inhibits 
HCV RNA replication in a dose-dependent manner. It is possible that PB1 
inhibits other targets including cellular factors required for RNA synthesis. 
However, PB1 can selectively block HCV RNA synthesis without influence 
on cellular RNA (β-actin) synthesis (data by RT-PCR, not shown). 
Therefore, it is likely that PB1 specifically suppresses HCV RNA replication. 
One of the possible mechanisms for inhibition of RNA replication is that 
PB1 acts as an HCV RNA polymerase inhibitor. Unfortunately, HCV RNA 
polymerase is not readily available at present. To strengthen this hypothesis, 
I examined whether PB1 inhibits the activity of T7 RNA polymerase in an 
enzymatic assay and demonstrated that PB1 directly inhibits T7 RNA 
polymerase activity (data not shown). But it does not provide a direct 
evidence of PB1 effect on HCV RNA polymerase. It is also required to 
determine the effects of PB1 on NS3 helicase or NS3/4A serine protease, 
since the inhibition of helicase or protease can also lead to the suppression of 
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HCV RNA synthesis. Further experiments are needed to reveal the detailed 
mechanism of HCV inhibition in future.  
Several studies showed that procyanidins can be absorbed in rats and 
humans [68-70]. Procyanidins were detected in the human plasma as early as 
30 min and reached the maximal concentrations by 2 h after oral 
administration [70]. Holt et al. reported that 2 h after the ingestion of a 
procyanidin-rich cocoa (0.375 g/kg) containing 256 mg procyanidin, the 
concentration of procyanidin B2 in human plasma reached 41 nM on 
average [70] indicating that oral administration of 62 g of cocoa 
procyanidins is needed to reach a plasma concentration of 10 µM. In another 
study, the concentrations of procyanidin B2 in human plasma reached 100 
nM after the consumption of cocoa (0.5 g/kg), of which 9.7 mg/g was 
procyanidins [71] indicating that 38 g of cocoa procyanidins is required to 
reach a plasma concentration of 10 µM at 2 h after oral administration. PB1 
showed moderate antiviral activity not only in my study but also in other 
studies [39, 57, 58], which reported antiviral activity at concentrations from 
1 µM to 100 µM. To improve the physiological concentration, certain 
chemical modifications that enhance plasma-stability and absorption of PB1 
should be required. The development of drug delivery systems may also 
enable to improve bioavailability and antiviral efficiency. Procyanidins, 
abundant in natural plant products including berries, grapes, cinnamon, and 
pycnogenol, have few adverse effects on normal cells compared to current 
therapeutic agents [72] suggesting that they may be good candidates as 
additional anti-HCV agents used in prolonged therapy. 
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There is an urgent need for easily administered, specific antiviral 
therapies capable of eliminating persistent HCV infection. Development and 
early clinical trials of STAT-C drugs designed to inhibit key viral enzymes, 
such as protease and polymerase, offer hope that this might be possible. In 
this study, I found a new anti-HCV compound, PB1, which might act as an 
HCV RNA replication inhibitor. This finding might open a door to have a 
further study about the antiviral effects of the other members in the 
procyanidin family. 
 
This study could contribute to the development of novel 
therapeutic strategies for the prevention and treatment of HCV. 
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7. CONCLUSION 
 
In this study, to develop novel anti-HCV agents, I evaluated antiviral 
activities in fractioned extracts of medicinal herbs and found that a catechin 
dimer purified from natural plants Cinnamomi cortex
Note: 
, PB1, suppresses HCV 
infection in vitro. Further study of antiviral mechanism demonstrated that 
PB1 might act as an HCV RNA replication inhibitor. This study could 
contribute to the development of novel therapeutic strategies for the 
treatment of HCV.  
 
 
Experiments of the plasmids used in this study had been approved by 
Tohoku University according to the Safety Management Regulation of 
Recombinant DNA experiments with the number of 76-21-46.  
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9. TABLES  
 
Table 1. Flow cytometric analysis of CD81 expression.  
 
PB1  
              CD81               CD71  
positive-staining cells %  MFI  positive-staining cells %  MFI  
Negative 96.5  9.53  98.1  11.8  
Positive 95.2  9.50  96.5  11.6  
 
Huh-7 cells were pretreated with or without PB1 (100 µM) at 37°C for 1 h. 
Cells were washed, detached, incubated with PE-conjugated CD81 or CD71 
(TfR) for 30 min at 4°C, and then subjected to flow cytometric analysis. 
Positive-staining cells and MFI (mean fluorescence intensity) are shown in 
this table.  
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10. FIGURES  
 
 
Figure 1. Schematic diagram of HCV life cycle 
Extracellular HCVvirions bind to receptor molecules on the cell surface and undergo 
clathrin-dependent endocytosis. After the entry, the virial nucleocapsid containing viral 
RNA genome is released into the cytoplasm. The genomic RNA is translated to a single 
large polyprotein that is processed into the 10 mature HCV proteins (Core, E1, E2, p7, 
NS2, NS3, NS4A, NS4B, NS5A and NS5B). The endoplasmic reticulum (ER) is 
modified by viral and cellular factors to form a membranous web, which is the major site 
of viral RNA replication. HCV nonstructural proteins support the RNA replication via 
synthesis of positive strands (+) from an intermediate negative strand (–) RNA template. 
The newly synthesized RNA is packaged into nucleocapsids. Virions get the outer 
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envelope composed of a lipid cell membrane and HCV envelope glycoproteins and then 
are released from the cell to complete the life cycle. The HCV life cycle mainly consists 
of entry, translation, RNA replication, assembly and release.  
 
 
 
Figure 2. Structures of PB1 and its components.  
Procyanidin, also known as oligomeric proanthocyanidin and condensed 
tannin is a class of flavanols, which take the form of oligomers or polymers 
of flavonoids. Procyanidin B1 (PB1) (A), a B type procyanidin, is a dimer of 
(-)-epicatechin (B) and (+)-catechin (C) by C4-C8 linkage.  
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Figure 3. Schematic diagrams of pseudotype viruses and HCV replicon.  
(A) VSV virus encodes five major proteins, which are nucleoprotein (N), 
phosphoprotein (P), matrix protein (M), glycoprotein (G) and large protein (L). 
Both VSV-based pseudotype viruses bearing HCV envelope proteins E1 and E2 
(HCVpv) or VSV glycoprotein (VSVpv) are containing the VSV genome, which 
glycoprotein G gene is replaced by the firefly luciferase reporter gene (Luc).  
(B) HCV replicon contains the 5’-NCR, the first 36 nucleotides of the core region 
fused directly with the firefly luciferase reporter gene (Luc), the internal ribosome 
entry site (IRES) element from encephalomyocarditis virus (EMCV) that directs 
translation of the HCV nonstructural (NS) proteins from NS3 to NS5B, and the 3’-
NCR. 5’-NCR contains an IRES element that is essential for cap-independent 
translation of HCV RNA. NS3 is a multifunctional protein with a serine protease 
located in the N-terminal one-third and an RNA helicase located in the C-terminal 
two thirds of the protein. The NS4A polypeptide functions as a cofactor for the 
NS3 serine protease. NS4B induces the formation of the membranous web. NS5A 
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is a phosphoprotein important for HCV RNA replication. NS5B is the RNA-
dependent RNA polymerase.  
 
 
Figure 4. Effects of PB1 on VSV-based pseudotype virus infection.  
Huh-7 cells were pretreated with various concentrations of PB1 for 1 h at 
37°C. The cells were then infected by VSVpv (A) or HCVpv (B) for 48 h. 
Experiments were performed in triplicate. The percentages of relative 
luciferase units (RLU) from means of three independent experiments ± 
standard deviations are shown.  
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Figure 5. Time of addition analysis of PB1 in Huh-7 cells.  
PB1 (100 µM) was added at the indicated time points (0, 1, 4, 8, 12 and 24 
h) after VSVpv (A) or HCVpv (B) infection in Huh-7 cells. The luciferase 
activity in the cells was measured after 48 h infection. Experiments were 
performed in triplicate. Relative luciferase unit (RLU) at 48 h is defined as 
100%. Results represent three independent experiments ±  standard 
deviations.  
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Figure 6. PB1 little inhibits viral binding and endocytosis in Huh-7 cells.  
Huh-7 cells were pretreated with various concentrations of chlorpromazine 
(A), MβCD (B), or PB1 (C) for 1 h at 37°C. The cells were then infected 
with VSV-G/HIVpv (5 ng of p24) at 37°C for 4 h. To determine the effects 
on viral binding, Huh-7 cells were incubated with PB1 (D) and VSV-
G/HIVpv (5 ng of p24) on ice for 4 h. The results are derived from three 
independent assays, with the error bars representing the standard deviations.  
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Figure 7. PB1 inhibits HCV replication.  
In vitro transcribed HCV replicon RNAs were transfected into Huh-7 cells. 
After 5 h, various concentrations of ribavirin (A), PB1 (B), (-)-epicatechin 
(C) and (+)-catechin (D) were added to the transfected cells. Luciferase 
activities were measured at 72 h post-transfection. Experiments were 
performed in triplicate. Relative luciferase unit (RLU) at 72 h in the cells 
without compounds was defined as 100%. Results were from at least three 
independent experiments ±  standard deviations. The black column 
represents the inhibition of HCV replication, and the black line represents 
the cytotoxicity of each compound.  
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